About Cypros Pharmaceuticals
Developer of therapeutic drugs for the treatment of disorders involving ischemia (impaired blood flow) such as stroke, traumatic head injury, heart attack, adult respiratory distress syndrome, and sepsis. The company has exclusive rights to two cytotherapeutic drug candidates, one of which is currently in clinical development. The candidate, CPC-111, reactivates anaerobic metabolism, a natural process whereby the life sustaining fuel adenosine triphosphate can be generated in ischemic conditions. The company is also pursuing the development of a new class of neuronal calcium channel blocker and a glial chloride channel blocker. Both drugs are designed to arrest cell damage early to treat the degenerative results of a stroke or injury-induced call trauma.